Hillevax Inc

NASDAQ HLVX

Download Data

Hillevax Inc Operating Cash Flow Per Share for the quarter ending March 31, 2024: -0.68

Hillevax Inc Operating Cash Flow Per Share is -0.68 for the quarter ending March 31, 2024, a -61.15% change year over year. Operating cash flow per share represents the amount of cash generated from a company's core operations per outstanding share. It is calculated by dividing the operating cash flow by the weighted average number of basic shares outstanding. This metric provides insights into the company's ability to generate cash flow from its day-to-day operations on a per-share basis. It is useful for evaluating the company's cash flow generation and comparing it with other companies on a per-share basis.
  • Hillevax Inc Operating Cash Flow Per Share for the quarter ending March 31, 2023 was -0.42, a -19.07% change year over year.
  • Hillevax Inc Operating Cash Flow Per Share for the quarter ending March 31, 2022 was -0.35, a -1,286.53% change year over year.
  • Hillevax Inc Operating Cash Flow Per Share for the quarter ending March 31, 2021 was -0.03.
NASDAQ: HLVX

Hillevax Inc

CEO Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date April 29, 2022
Location United States
Headquarters 75 State Street, Boston, MA, United States, 02109
Employees 90
Sector Healthcare
Industry Biotechnology
Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

ELYM

Eliem Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

VIGL

Vigil Neuroscience Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

STRO

Sutro Biopharma

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email